Made Therapeutics, Inc. entered into letter agreement to acquire Debut Diamonds Inc. (CNSX:DDI) from Jason I. Goldman Professional Corporation, Marc Lustig, Steven Mintz, Camille Rabay, Rajiv Bhatia,Greg Wilson and others in a reverse merger transaction on February 2, 2021. Pursuant to the terms of the agreement, Debut Diamonds will effect a consolidation of its issued and outstanding common shares prior to completion of the transaction. In accordance with the terms of the transaction, the holders of the issued and outstanding ordinary shares in the capital of Wesana Health will be issued one consolidated Debut Share or an economically equivalent number of super voting shares or multiple voting shares in exchange for every one Wesana Health share held immediately prior to the completion of the transaction. Outstanding convertible notes of Wesana Health will be converted into Wesana Health shares. The resulting Wesana Health shares issued on conversion will be exchanged for shares of the resulting issuer based on the exchange ratio. In connection with the transaction, Wesana Health will complete a brokered private placement of gross proceeds of up to CAD 15 million. The resulting issuer will trade under the name Wesana Health Holdings Inc. It is anticipated that trading of the Debut Shares on the CSE will be halted until the transaction is completed.

Upon Closing, all of Debut Diamonds current directors and executive officers will resign and the board of directors and executive officers of the resulting issuer will be comprised of the nominees of Wesana Health. The completion of the transaction is subject to a number of conditions, including but not limited to completion of the private placement, regulatory, Debut Diamond shareholders corporate and third-party approvals. The shareholder meeting will be held on April 1, 2021. The board of Debut Diamond has unanimously approved the transaction and recommend Debut Diamond shareholders to vote for the transaction. As of April 28, 2021, Wesana Health Inc. and Debut Diamonds Inc. have obtained conditional approval from the Canadian Securities Exchange for the listing of the subordinate voting shares that will result from the previously announced reverse takeover of Debut by Wesana. The transaction is expected to close in the first half of 2021. Capital Transfer Agency Inc. acted as transfer agent for Debut Diamonds.

Made Therapeutics, Inc. completed the acquisition of Debut Diamonds Inc. (CNSX:DDI) from Jason I. Goldman Professional Corporation, Marc Lustig, Steven Mintz, Camille Rabay, Rajiv Bhatia,Greg Wilson and others in a reverse merger transaction on May 6, 2021. Upon completion of the Transaction, the registered office of the surviving entity will be located at Suite 2200 – 885 West Georgia Street, Vancouver, British Columbia V6C 3E8 and the head office of the Resulting Issuer will be located at 13236 West Chicago Bloomington Trail, Homer Glen, IL 60491, U.S.A. As of April 28, 2021, Wesana Health received the conditional approval from the Canadian Securities Exchange for the listing of the Subordinate Voting Shares that resulted from the closing of the Reverse Takeover. The Wesana Health expects to commence trading on the CSE on or about May 10, 2021 under the symbol “WESA.”. Following the Reverse Takeover, the leadership team of Wesana is as follows: Daniel Carcillo as Chief Executive Officer and Director, Zed Wang as Chief Financial Officer, Mark Wingertzahn as Chief Scientific Officer, Dawn McCollough as Chief Operating Officer, Stephan Bart as Chief Medical Officer, Israel Mirsky as Chief Strategy Officer, Chad Bronstein as Executive Chairman, Mitch Kahn, Robert Koffman and George Michael Steinbrenner IV as Director. The deal was subject to approvals of Wesana Health shareholders, the conditional approval of CSE for the listing of Debut consolidated shares, all directors, officers and members of management of Acquiror shall have delivered resignations, Voting Support Agreements (as defined herein) shall have been entered. Odyssey Trust Company is the transfer agent to Wesana Health.